GEORGETOWN, Texas (PRWEB) November 20, 2018
On November 1, 2018, a product agreement went into effect between ORTHOReBIRTH USA and Adventist Health System Sunbelt Healthcare Corporation (AHS), a faith-based healthcare organization with a tradition of caring for the physical, emotional and spiritual needs of every patient.
“AHS has such a notable reputation within the industry,” says Doris Blake, COO of ORTHOReBIRTH USA, “so we are very excited to have partnered with them.”
ORTHOReBIRTH USA markets ReBOSSIS®, the only biosynthetic scaffold with electrospun microfiber construction. ReBOSSIS® supports cell activation, retention and proliferation and has a demonstrated 54 percent compression recovery rate.
This product agreement is following some more big news for ORTHOReBIRTH USA, as just a year ago, the Food and Drug Administration cleared ReBOSSIS® for a new indication. Recently, ORTHOReBIRTH USA also signed a letter of intent with Dr. Loubert S. Suddaby to develop new biologics, as well as signed a supplier agreement with Resource Optimization & Innovation, LLC.
About Adventist Health System
Adventist Health System was founded in 1973, to support and strengthen the Seventh-Day Adventist healthcare organizations in the Southern and Southwestern regions of the United States. Today, it is a national leader in quality, safety and patient satisfaction, comprised of 48 hospital campuses and more than 80,000 employees.
About ORTHOReBIRTH USA
ORTHOReBIRTH USA recognizes the challenges associated with orthopedic surgery—for patients, surgeons and hospitals alike. We are committed to marketing cutting-edge orthopedic biologics that improve patients’ quality of life and offer superior outcomes. We have carried out extensive studies on what makes biologic materials successful and have used that knowledge to engineer world-class products for use in a host of orthopedic surgical procedures. ORTHOReBIRTH USA is proud to market premium orthopedic biologics to surgeons practicing around the world. Recently, ORTHOReBIRTH USA also signed a letter of intent with Dr. Loubert S. Suddaby to develop new biologics.